Supriya Lifescience Limited (BOM:543434)

India · Delayed Price · Currency is INR

915.05

+15.30 (1.70%)

At close: Oct 6, 2026

Market Cap	73.67B +25.2%
Revenue (ttm)	8.73B +28.1%
Net Income	1.98B +11.4%
EPS	24.65 +11.4%
Shares Out	n/a
PE Ratio	37.14
Forward PE	n/a
Dividend	1.00 (0.11%)
Ex-Dividend Date	Sep 4, 2026

Volume	12,921
Open	901.00
Previous Close	899.75
Day's Range	885.60 - 916.95
52-Week Range	545.65 - 1,085.50
Beta	n/a
Analysts	Buy
Price Target	940.00 (+2.73%)
Est. Earnings	Nov 13, 2026

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals in India and internationally. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides finished formulation products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1987

Employees 607

Stock Exchange Bombay Stock Exchange

Ticker Symbol 543434

Full Company Profile

Financial Performance

In fiscal year 2026, Supriya Lifescience's revenue was 8.28 billion, an increase of 18.86% compared to the previous year's 6.96 billion. Earnings were 2.09 billion, an increase of 11.26%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 543434 stock is "Buy." The 12-month stock price target is ₹940.00, which is an increase of 2.73% from the latest price.

Price Target

₹940.00

(2.73% upside)

Analyst Consensus: Buy

Stock Forecasts